NimaGen
Private Company
Funding information not available
Overview
NimaGen is a private, revenue-generating company providing tools and reagents for DNA sequencing, with a core focus on its patented Reverse Complement PCR (RC-PCR) technology. This platform enables single-reaction NGS library preparation, reducing workflow complexity and improving sample traceability. The company serves a global customer base across diagnostics and research, offering solutions for infectious disease, human genetics, and forensic applications while maintaining strong support for established Sanger sequencing and capillary electrophoresis systems.
Technology Platform
Patented Reverse Complement PCR (RC-PCR) technology enabling single-tube, single-reaction NGS library preparation through simultaneous multiplexing, indexing, and amplification.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
NimaGen competes in the NGS sample prep market against giants like Illumina, Thermo Fisher Scientific, and QIAGEN, who offer proprietary, often platform-tied kits. Its differentiation lies in its single-reaction RC-PCR technology, vendor agnosticism, and focus on specific high-value applications like forensics and infectious disease where workflow simplicity and sample integrity are critical.